| укр | рус |



No2-3(2) 2019

Back to the issue

DOI 10.37219/2528-8253-2019-2-58

Bezshapochny S, Hychak I
Optimal therapy of inflammatory diseases in the risk groups
Bezshapochny Sergey B.
Ukrainian Medical Stomatological Academy
Head of Department of oto-rhino-laryngology with ophthalmology
Doctor of Medical Sciences, Professor.

Hychak Irina
Ukrainian Medical Stomatological Academy
Department of oto-rhino-laryngology with ophthalmology


Topicality: Pregnant women are at increased risk of susceptibility to inflammatory diseases of the pharynx.
Unfortunately, there are currently no approved protocols for the treatment of ENT diseases for such patients in Ukraine. It is very important to choose a safe and effective drug with minimal absorption in to the general blood flow. Another important point for the doctors the legal aspect, namely, the absence of contraindications to the appointment of pregnant women in the instructions for use of the medicine. These criteria are met by Celista spray for a throat, which is based on the active substance miramistin (0.1 mg/ml).
Materials and methods: We conducted a study that involved 30 pregnant women. These lection criteria were pregnant women from I to III trimester with a diagnosis of acute pharyngitis / tonsillitis / tonsillopharyngitis, up to 5 days after the disease, 0-3 points on a modified McAizek-Center scale, voluntary consent and adequate attitude to the study. All patients were prescribed topical irrigation of Celista spray x 4 times a day. The examination complex included subjective assessment of the condition on a 10-point visual-analogue scale, symptom severity assessment was performed using a questionnaire on a 4-point scale by criteria such as sore throat, burning, coughing (0 – no symptom, 1 – the symptom is poorly expressed, 2 – the symptom is moderately expressed, 3 – the symptom is strongly expressed). Objective examination included assessment of the condition by criteria such
as hyperemia of the posterior pharyngeal wall; hypertrophy of the follicles of the posterior wall of the pharynx; hypertrophy and swelling of the tonsils; regional lymphadenitis for 0; 3; 5; 7 days.
Results: It was found that the pain index decreased by 1.6 points, laceration in the throat – by 1.78 points, cough – by 0.3 points after treatment. A similar tendency was observed in the objective status: hyperemia of the posterior pharyngeal wall decreased by 1.5 points, hypertrophy of the pharynx follicles – by 1.27 points, hyperemia and swelling of the tonsils – by 0.8 points, regional lymphadenitis – by 0.5 points.
Conclusion: Thus, given that the absorption of Celista spray is actually absent, the drug has no contraindications for prescription during pregnancy, and based on our results, we can confirm the effectiveness of its use during pregnancy for the local treatment of acute inflammatory diseases of the pharynx in pregnant women in any period.


pharyngitis, tonsillitis, pregnancy, miramistin, celista. 


  1. Bathala S, Eccles R. A review on the mechanism of sore throat in tonsillitis. J Laryngol Otol. 2013;127(3):227-32.
    doi: 10.1017/S0022215112003003.
  2. Alrefaei MA, Alzahrani MA. Overview of management approaches of acute tonsillitis diagnosis in primary care. Int J Sci Eng Res. 2018;9(1): 1560-72.
  3. Bezshapochny SB, Ivanchenko SA, Gichak IS. [Features of the combined treatment of inflammatory diseases of the pharynx]. World of Medicine and Biology. 2018; 64(2): 12-5. doi: 10.26724/2079-8334-2018-2-64-12-15. [Article in Ukrainian].
  4. Choby BA. Diagnosis and treatment of streptococcal pharyngitis. Am Fam Physician. 2009 Mar 1; 79(5): 383-90.
  5. Zaritskaya IS. [Features of drug therapy of ENT diseases during pregnancy (literature review)]. Zhinochiy lIkar.
    2007; 4: 32-5. [Article in Russian].
  6. Pukhlik SM, Titarenko OV, Kolesnichenko VV. [Pharmacotherapy of ENT diseases in pregnant women]. Zdorov’ya Ukrayini. 2015; 3(31): 42-7. [Article in Russian].
  7. Instructions for use of the drug CELISTA®. Available from: files/celista_rozchin_ukr.pdf [In Ukrainian].

© 2019, Public Organization «Ukrainian Scientific Medical Society of Otorhinolaryngologists»